Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 12
January 07 2021 - 4:15PM
Royalty Pharma plc (Nasdaq: RPRX) today announced that management
will present at the 39th Annual J.P. Morgan Healthcare Conference
on Tuesday, January 12, 2021 at 10:50 a.m. EST.
Investors, analysts, members of the media and
the general public are invited to listen to a live webcast of the
presentation at
https://www.royaltypharma.com/investors/news-and-events/events. A
replay of the webcast will be archived on the company's website for
at least 30 days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest
buyer of biopharmaceutical royalties and a leading funder of
innovation across the biopharmaceutical industry, collaborating
with innovators from academic institutions, research hospitals and
not-for-profits through small and mid-cap biotechnology companies
to leading global pharmaceutical companies. Royalty Pharma has
assembled a portfolio of royalties which entitles it to payments
based directly on the top-line sales of many of the industry’s
leading therapies. Royalty Pharma funds innovation in the
biopharmaceutical industry both directly and indirectly - directly
when it partners with companies to co-fund late-stage clinical
trials and new product launches in exchange for future royalties,
and indirectly when it acquires existing royalties from the
original innovators. Royalty Pharma’s current portfolio includes
royalties on more than 45 commercial products, including AbbVie and
J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s
Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’
Promacta, and Vertex’s Kalydeco, Symdeko, Orkambi and Trikafta, and
four development-stage product candidates. For more information,
visit www.royaltypharma.com.
Royalty Pharma Investor Relations and
Communications
+1 (212) 883-2295ir@royaltypharma.com
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Sep 2023 to Sep 2024